转自：推广 12月7日，以岭药业（002603.SZ）发布公告称，根据国家医疗保障局网站发布的《关于印发〈国家基本医疗 保险、生育保险和工伤保险药品目录〉以及〈商业健康保险创新药品目录〉（2025年）的通知》，其独家产 品芪防鼻通片通过医保谈判，首次被纳入国家医保目录。据悉，芪防鼻通片为首个说明书明确治疗持续性变 应性鼻炎（即过敏性鼻炎）的创新中药，填补临床用药空白。 作为中国中医药行业的领军企业，以岭药业积极响应国家大健康战略号召，始终将研发创新视为企业发展的 核心驱动力，长期保持高强度的研发投入。最新数据显示，2025年前三季度，以岭药业研发费用达5.44亿 元，营收占比达9.27%；2019至2024年间，以岭药业研发投入累计超过50亿元，持续领先于行业平均水平。 这些投入为公司构建了覆盖理论创新、药物研发、循证医学研究到产业化应用的全链条科研体系，为持续创 新提供了坚实保障。 在创新药物研发方面，以岭药业取得了显著成果。目前，公司拥有专利中药17个，覆盖心脑血管系统、感冒 呼吸系统、内分泌系统、肿瘤等8大临床疾病系统，其中12个品种纳入国家医保目录，5个进入国家基本药物 目录，展现了广泛的市场认可度和 ...

Core Insights - Tong Ren Tang achieved a revenue of 18.597 billion yuan in 2024, marking a year-on-year growth of 4.12%, with a net profit attributable to shareholders of 1.526 billion yuan [2] - The company's revenue primarily comes from its pharmaceutical manufacturing and commercial sectors, with significant contributions from cardiovascular products and tonics [2][6] - The company continues to enhance its brand image and market presence through governance reforms and marketing strategies, while also focusing on sustainable development and ESG principles [3][6] Financial Performance - In 2024, cardiovascular products generated revenue of 5.146 billion yuan, a year-on-year increase of 17.26%, while tonic products saw revenue of 2.127 billion yuan, up 22.98% [2] - The company distributed a total cash dividend of 1.371 billion yuan, representing 89.86% of the net profit for the year, reflecting strong profitability and commitment to shareholder returns [7] Market Expansion - Tong Ren Tang's subsidiary in Hong Kong reported revenue of 1.07 billion HKD in 2024, a growth of 16.9%, with an increase of 2 stores compared to the previous year [4] R&D and Innovation - The company is intensifying its R&D efforts, launching new products that meet market demands, and completing clinical studies for various traditional Chinese medicine formulations [6] - Investments in digital production lines and supply chain management are enhancing operational efficiency and modernizing manufacturing processes [6] Governance and Marketing - The company is implementing targeted performance metrics for subsidiaries based on their business models, focusing on cost reduction and efficiency improvements [3] - Marketing strategies are being unified to leverage product group advantages, while initiatives like "Tong Ren Tang Day" are enhancing brand promotion [3]